Barclays analyst Andrew Mok raised the firm’s price target on HCA Healthcare (HCA) to $551 from $494 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 report. HCA’s 2026 core growth of 6%-9% came in well ahead of expectations, and there remains earnings upside from both a late cycle Affordable Care Act subsidy extension and pending state directed payment programs, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Earnings Call: Growth Amid Policy Strain
- HCA Healthcare price target raised to $540 from $485 at BofA
- Early notable gainers among liquid option names on January 27th
- Morning Movers: Managed care group slide after CMS notice
- HCA Healthcare Posts Strong Q4 Results, Boosts Capital Returns